ACH earnings

Accendra Health, Inc. (NYSE:ACH) (the Company) announced today that its Board of Directors adopted a Section 382 Rights Agreement (the "Tax Asset Preservation Plan") designed to protect long-term shareholder value by facilitating the Company’s ability to preserve its net operating loss carryforwards ("NOLs") and certain other tax attributes. A company generally experiences an ownership change if the percentage of the value of its stock owned by certain "5-percent shareholders," as such term is defined in Section 382 of the Code, increases by more than 50 percentage points over a rolling three-year period. The Tax Asset Preservation Plan is intended to reduce the likelihood of such an "own

Reduced Total Debt By $385 Million In Second Quarter CEO Ed Pesicka Announces Intention To Retire By The End of 2026 Accendra Health, Inc. (NYSE:ACH) (the Company) today reported financial results for the second quarter ended June 30, 2026. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which represent what was previously the Patient Direct segment and certain functional operations. "Throughout the second quarter, we moved farther along toward the complete separation from Owens & Minor while also putting a large commercial payor exit behind us. In the last six months, we have eliminated well over $125 million of annualized operating expense direc

Accendra Health, Inc. (NYSE:ACH) (the Company) today announced that President and Chief Executive Officer Edward A. Pesicka has informed the Board of Directors of his plan to retire by the end of 2026, after more than seven years with the Company. Mr. Pesicka will also retire from the Company’s Board of Directors before the end of the year. The Board of Directors maintains a long-standing, robust succession planning process established to address officer succession. Through that process, the Board has previously identified potential candidates with the capabilities to succeed Mr. Pesicka. With Mr. Pesicka’s decision and announcement, the Board will leverage that preparation to comprehensive

Accendra Health, Inc. (NYSE:ACH) (the "Company") plans to release financial results for the second quarter of 2026 on Monday, August 10, 2026, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Accendra Health website available at investors.accendra.com/events-and-presentations/. A repla

Commitments in Place from Existing Creditors to Strengthen Balance Sheet, Extend Maturities, and Reduce Leverage Accendra Health, Inc. (NYSE:ACH) today reported financial results for the first quarter ended March 31, 2026, and announced a more than $1.5 billion comprehensive balance sheet optimization transaction with commitments from existing creditors that will strengthen the balance sheet, significantly extend maturities and reduce total leverage. Unless otherwise noted, the results herein reflect the Company's continuing operations, which represent what was previously the Patient Direct segment and certain functional operations. "Our first quarter results were aligned with our expec

Accendra Health, Inc. (NYSE:ACH) (the "Company") plans to release financial results for the first quarter of 2026 on Monday, May 11, 2026, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:30 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Accendra Health website available at investors.accendra.com/events-and-presentations/. A replay of

Completed Sale of Products & Healthcare Services Business On December 31, 2025 Strong Cash Flow and Debt Reduction In Quarter Accendra Health, Inc. (NYSE:ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect the Company's continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations. "We ended the fourth quarter with the completion of the sale of the Products & Healthcare Services (P&HS) business on December 31, 2025, and we are extremely excited to embark on the next chapter of our business as Accendra Health. The next several months w

Accendra Health, Inc. (NYSE:ACH) (the "Company") plans to release financial results for the fourth quarter of 2025 on Thursday, February 19, 2026, after trading ends on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 5:00 p.m. EST on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Accendra Health website available at investors.accendra.com/events-and-presentations/. A repl